冠军工业(CHMP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CHMP 冠军工业

休市中 12-05 16:00:00 EST 延时

{"stockData":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"冠军工业","latestPrice":0.0001,"timestamp":1764968400000,"preClose":0.0001,"halted":0,"volume":0,"delay":15,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"休市中","change":0,"latestTime":"12-05 16:00:00 EST 延时","open":0.0001,"high":0.0001,"low":0.0001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0001,"volumeRatio":0.8955217197599107},"requestUrl":"/m/hq/s/CHMP","defaultTab":"news","newsList":[{"id":"2583550301","title":"甘李药业(603087.SH)：甘精胰岛素注射液(Ondibta®)上市许可申请(MAA)获得欧盟CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2583550301","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583550301?lang=zh_cn&edition=full","pubTime":"2025-11-13 17:17","pubTimestamp":1763025442,"startTime":"0","endTime":"0","summary":"CHMP 建议欧盟委员会批准甘精胰岛素注射液作为 Lantus SoloStar 的生物类似药上市，用于治疗成人、青少年和2岁及以上儿童的糖尿病。CHMP的建议将进入EC审查阶段，以获得Ondibta在欧盟、冰岛、列支敦士登和挪威的上市许可，最终决定预计将于明年初做出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4215","603087","BK0239","BK4087","CHMP","MAA","BK4588","FSXEmain","BK4585","FESXmain"],"gpt_icon":0},{"id":"2555608579","title":"港股异动 | 复宏汉霖(02696)涨超3% 近日HLX14获欧洲药品管理局CHMP积极评审意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2555608579","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555608579?lang=zh_cn&edition=full","pubTime":"2025-07-29 10:30","pubTimestamp":1753756255,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖涨超3%，截至发稿，涨3.31%，报71.9港元，成交额3831.84万港元。消息面上，复宏汉霖发布公告，近日，HLX14获欧洲药品管理局人用医药产品委员会积极审评意见，推荐批准HLX14的上市许可申请。CHMP的审评意见将会被递交至欧盟委员会，EC将参考该意见并在未来2-3个月做出最终审查决定。一旦获得EC批准，HLX14的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CHMP","02696","BK1161","BK4087"],"gpt_icon":0},{"id":"2554877836","title":"复宏汉霖(02696)：地舒单抗生物类似药HLX14(重组抗RANKL全人单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2554877836","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554877836?lang=zh_cn&edition=full","pubTime":"2025-07-28 18:17","pubTimestamp":1753697873,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，HLX14获EMA人用医药产品委员会(Committee for Medicinal Products for Human Use，“CHMP”)积极审评意见，推荐批准HLX14的上市许可申请。CHMP的审评意见将会被递交至欧盟委员会(European Commission，“EC”)，EC将参考该意见并在未来2-3个月做出最终审查决定。一旦获得EC批准，HLX14的集中上市许可将在所有欧盟成员国及欧洲经济区(EEA)国家冰岛、列支敦士登和挪威生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CHMP","02696","BK1574","BK4081","BK1161","09939","159938","EMA","BK1515","BK4087"],"gpt_icon":0},{"id":"2554795973","title":"吉利德科学升2.3% 公司HIV预防药获CHMP加速审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2554795973","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554795973?lang=zh_cn&edition=full","pubTime":"2025-07-25 22:59","pubTimestamp":1753455573,"startTime":"0","endTime":"0","summary":"金吾财讯 | 吉利德科学(GILD)股价上扬，截至发稿，涨2.31%，报115.81美元。公司今日宣布，欧洲药品管理局（EMA）下属人用药品委员会（CHMP）已通过加速审评程序出具积极审评意见，推荐该公司HIV-1衣壳抑制剂注射剂lenacapavir用于暴露前预防（PrEP），以降低存在HIV-1感染风险的成年及青少年群体经性行为感染该病毒的概率。最终审批决定预计于今年晚些时间公布，若获批上市，该药物将以商品名Yeytuo®在欧盟地区销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072523004094bad418&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072523004094bad418&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU0234570918.USD","IE00BKVL7J92.USD","BK4550","LU0823416689.USD","LU1674673691.USD","LU2089984988.USD","BK4139","SG9999015952.SGD","IE00B19Z3B42.SGD","LU0058720904.USD","LU2087621335.USD","LU1430594728.SGD","SG9999015945.SGD","IE00BSNM7G36.USD","LU1674673428.USD","CHMP","LU2468319806.SGD","BK4087","LU1066053197.SGD","BK4566","BK4532","SG9999015978.USD","IE00B3T34201.USD","BK4583","BK4588","LU1585245621.USD","LU0109394709.USD","IE0002270589.USD","SG9999015986.USD","IE00B19Z3581.USD","LU1839511570.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","GILD","IE00B7SZLL34.SGD","LU0289739699.SGD","BK4578","LU0320765992.SGD","LU0889565916.HKD","LU1066051498.USD","LU2324357040.USD","LU1571399168.USD","BK4585"],"gpt_icon":0},{"id":"2508144241","title":"美股前瞻 | 三大股指期货齐跌，特朗普“TRUMP币“吸金亿元但散户血亏，本周聚焦1月非农","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144241","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508144241?lang=zh_cn&edition=full","pubTime":"2025-02-03 19:54","pubTimestamp":1738583675,"startTime":"0","endTime":"0","summary":"2月3日(周一)美股盘前，美股三大股指期货齐跌。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20250203/20250203195100_91447.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250203/20250203195100_91447.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a957e6eb7173a243f86732cf5b68dbd3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1245425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","BK4588","BK4087","BK4601","CHMP","BK4594"],"gpt_icon":1},{"id":"2484564742","title":"一哥的业绩，投资人不买账","url":"https://stock-news.laohu8.com/highlight/detail?id=2484564742","media":"并购菁英汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484564742?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:03","pubTimestamp":1731924185,"startTime":"0","endTime":"0","summary":"按理说，百济神州拳头产品取得强势的增长且公司非GAAP净利润连续第二个季度实现盈利的背景下，公司股价并未像今年二季度业绩公布前后实现市值的显著提升，相反资金却选择了短期内对其进行抛售。显然，百济神州2024Q3费用控制层面让投资者认为有不及预期的地方。尽管百济神州作为海外PD-1市场的后发者，但获批适应症患者数量众多，叠加近日FDA限制已上市部分PD-1在胃癌适应症上的使用，替雷利珠单抗存在一定差异化优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK4535","06160","BGNE","BK4588","BK4504","BK4585","BK4505","LU0053666078.USD","BK4526","CHMP","BK4139","BK4548","L","BK4087","BK4107"],"gpt_icon":0},{"id":"2482705245","title":"摸不准的AD市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2482705245","media":"佰傲谷BioValley","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482705245?lang=zh_cn&edition=full","pubTime":"2024-11-12 20:02","pubTimestamp":1731412920,"startTime":"0","endTime":"0","summary":"刚刚披露的渤健第三季度财报中，两家公司推出的第二款AD药物Leqembi的销售表现还被认为超出市场预期，然而风向一转，Leqembi的销售预期就又被下调了。时隔半年，Leqembi就获得FDA完全批准，成为第一个真正意义上获得FDA认可的AD新药。在去年AD市场上只有这一款Aβ单抗在市销售的情况下，Leqembi总共才卖了1000万美元——远低于市场预期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-12/doc-incvvkhc6095242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CHMP","BK4087"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.champion-industries.com","stockEarnings":[{"period":"1week","weight":-0.0313},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.1071},{"period":"6month","weight":0.1071},{"period":"1year","weight":0.069},{"period":"ytd","weight":-0.225}],"description":"2450 First Avenue P.O. Box 2968 Huntington West Virginia","exchange":"EXPERT","name":"冠军工业","nameEN":"Champion Industries, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"冠军工业(CHMP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供冠军工业(CHMP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"冠军工业,CHMP,冠军工业股票,冠军工业股票老虎,冠军工业股票老虎国际,冠军工业行情,冠军工业股票行情,冠军工业股价,冠军工业股市,冠军工业股票价格,冠军工业股票交易,冠军工业股票购买,冠军工业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"冠军工业(CHMP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供冠军工业(CHMP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}